Real Time fMRI and Quitting Smoking
A Proof-of-concept Study of Real-time fMRI Neurofeedback Training for Smoking Cessation
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- University of Pennsylvania
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Treatment-seeking smokers between the ages of 18 and 65, reporting consumption of at least 10 cigarettes per day for at least the past 6 months;
- Planning to live in the area for at least the next month;
- Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the combined consent and HIPAA form;
- Able to communicate fluently in English (speaking, writing, and reading).
Exclusion Criteria:
Smoking Behavior:
- Use of chewing tobacco or snuff or cigars;
- Current enrollment or plans to enroll in another smoking cessation program or research study in the next month;
- Current or anticipated (within the next month) use of smoking cessation medications or nicotine replacement therapy (NRT);
- A baseline carbon monoxide (CO) reading less than 10ppm.
Alcohol/Drugs:
- Current alcohol consumption that exceeds 25 standard drinks/week;
- Positive breath alcohol concentration test (BrAC greater than or equal to 0.01) at intake; a. Participants testing positive for breath alcohol with a reading equal to or greater than .08 (the legal driving limit) or who are visibly impaired will be instructed not to drive themselves home after the appointment. If a participant needs to use a phone to call for a safe ride home, an office telephone will be made available to the participant.
Medication:
Current use or recent discontinuation (within the past 30 days at the time of Intake) of:
- Smoking cessation medication (e.g., Zyban, Wellbutrin, Wellbutrin SR, Chantix, NRT);
- Anti-psychotic medications;
Any medication that could compromise participant safety as determined by the Principal Investigator and/or Study Physician;
Daily use of:
- Opiate-containing medications for chronic pain.
Medical/Neuropsychiatric:
- Women who are pregnant, planning a pregnancy, and/or breast feeding. All female subjects of childbearing potential will undergo a urine pregnancy test at Intake and at each scan session.
- History of epilepsy or a seizure disorder;
- History of stroke;
- Self-reported brain (or CNS) or spinal tumor;
- Self-reported history of head trauma;
- Self-reported history or current diagnosis of psychosis.
fMRI-Related:
- Self-reported use of pacemakers, certain metallic implants, or presence of metal in the eye as contraindicated for fMRI;
- Self-reported history of claustrophobia;
- Being left-handed;
- Color blindness;
- Weight greater than 250lbs at intake;
- Self-reported history of gunshot wounds;
- Any impairment preventing participants from using the response pad necessary for the computer tasks;
- Circumstances or conditions that may interfere with magnetic resonance imaging (MRI).
General Exclusion:
- Any medical condition, illness, disorder, or concomitant medication that could compromise participant safety or treatment, as determined by the Principal Investigator;
- Enrollment or plans to enroll in another research study;
- Inability to provide informed consent or complete any of the study tasks as determined by the Principal Investigator.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Real-time neurofeedback training group
We propose to use rt-fMRI neurofeedback training to help smokers consciously modulate activation in areas related to cravings and self-control in order to improve control smoking urges.
In this arm, participants will complete four sessions: an intake session and 3 neurofeedback scanning visits.
The primary outcome is the ability to resist smoking during a validated smoking lapse paradigm.
Secondary outcomes include changes in brain activity in areas related to craving and self-control, and self-reported craving for cigarettes.
|
Real-time fMRI (rt-fMRI) allows for rapid analysis of brain activation while an individual is actively performing a task, and can be used to provide real-time neurofeedback to individuals during fMRI scanning.
Using neurofeedback, individuals can learn to modulate activity in specific regions of the brain.
We propose to use rt-fMRI neurofeedback training to help smokers consciously modulate activation in areas related to cravings and self-control in order to improve control smoking urges.
Participants will complete four sessions: an intake session and 3 scanning visits.
The primary outcome is the ability to resist smoking during a validated smoking lapse paradigm.
|
|
No Intervention: No-feedback control group
We propose to use rt-fMRI neurofeedback training to help smokers consciously modulate activation in areas related to cravings and self-control in order to improve control smoking urges.
In the control group arm, participants will complete four sessions: an intake session and 3 scanning visits with no neurofeeback.
The primary outcome is the ability to resist smoking during a validated smoking lapse paradigm.
Secondary outcomes include changes in brain activity in areas related to craving and self-control, and self-reported craving for cigarettes.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Smoking Lapse Paradigm
Time Frame: Study session 3 (scan day 3)
|
Time (sec) to first cigarette during a 50 minute monitored smoking lapse period in smoking laboratory
|
Study session 3 (scan day 3)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Cue induced brain signal change
Time Frame: Study session 3 (scan day 3)
|
Change in mean percent signal change for Cue minus Neutral contrasts in activated brain regions
|
Study session 3 (scan day 3)
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 828012
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Nicotine Use Disorder
-
NCT05897242CompletedNicotine Dependence | Nicotine Use Disorder | Nicotine Vaping | Vaping | Nicotine Addiction
-
NCT06259630WithdrawnNicotine Use Disorder | Nicotine Addiction
-
NCT03352609TerminatedNicotine Dependence | Nicotine Use Disorder
-
NCT00330187CompletedNicotine Dependence | Nicotine Use Disorder
-
NCT07210268RecruitingSubstance Use Disorders | Nicotine Use Disorder
-
NCT03194958CompletedSmoking | Smoking Cessation | Tobacco Use | Tobacco Smoking | Tobacco Use Cessation | Nicotine Dependence | Tobacco Dependence | Smoking, Tobacco | Nicotine Use Disorder | Nicotine Dependence, Cigarettes
-
NCT05994209RecruitingNicotine Use Disorder | Nicotine Vaping
-
NCT06798324RecruitingSmoking Cessation | Tobacco Smoking | Tobacco Use Disorder | Substance Use Disorders | Nicotine Dependence | Nicotine Use Disorder
-
NCT00257894TerminatedSmoking | Tobacco Use Disorder | Nicotine Dependence | Nicotine Use Disorder
-
NCT00429208UnknownSmoking | Tobacco Use Disorder | Nicotine Dependence | Nicotine Use Disorder
Clinical Trials on Realtime biofeedback using fMRI
-
NCT05621538RecruitingAlcohol Use Disorder
-
NCT06387563Recruiting
-
NCT00177541CompletedUrge Urinary Incontinence
-
NCT06049784RecruitingObstetric Labor Complications | Obstetric Trauma
-
NCT07065708RecruitingPhysiotherapy | Pelvic Floor Dysfunction | Postpartum | Pelvic Floor Health After Childbirth | Pelvic Floor Muscle Training | Pelvic Floor Muscle Exercise | Pelvic Floor Disorder | Physiotherapy Specialty | Pelvic Floor, Obstetric | Transperineal Ultrasound
-
NCT03499574CompletedStroke, Acute | Dysphagia, Oropharyngeal
-
NCT06226688CompletedBreast Cancer Female
-
NCT02193932Completed